Geron CORP 8-K filings

Geron Corporation announced second quarter 2026 financial results, highlighting an 11% increase in RYTELO net product revenue to $57.5 million and reiterating full-year revenue and expense guidance.

Geron Corporation's stockholders approved an amendment to the 2018 Equity Incentive Plan, increasing share availability, and re-elected three Class III directors at the 2026 Annual Meeting.

Geron Corporation announced the immediate election of Patricia S. Andrews and Constantine Chinoporos to its Board of Directors, enhancing governance and strategic oversight.

Geron Corporation announced fourth quarter and full year 2025 financial results, highlighting significant RYTELO revenue growth and a reduced net loss, alongside 2026 guidance.

Geron Corporation announced its 2026 financial guidance, projecting RYTELO net product revenue between $220 million and $240 million, alongside a reduction in operating expenses.

Geron Corporation amended its senior secured term loan facility, extending the availability of Tranches B and C and the makewhole date for prepayments.

Geron Corporation initiated a strategic restructuring plan, including a one-third workforce reduction, to improve financial discipline and create long-term shareholder value.

Geron Corporation announced its third-quarter 2025 financial results, reporting $47.2 million in RYTELO net product revenue and key clinical and corporate advancements.

Geron Corporation announced significant executive and board leadership transitions, including the appointment of a new Chief Commercial Officer and three other seasoned executives, to align with strategic priorities.

Geron Corporation announces the appointment of Harout Semerjian as its new President and Chief Executive Officer, effective August 7, 2025, alongside significant compensation and equity plan adjustments.

Geron Corporation announced robust second-quarter 2025 financial results, including significant RYTELO net product revenue growth and the appointment of Harout Semerjian as President and CEO.

Geron Corporation announced that its stockholders approved amendments to both its 2018 Equity Incentive Plan and 2014 Employee Stock Purchase Plan, increasing the shares available for issuance by 20 million and 6 million, respectively, at the 2025 Annual Meeting.

Geron Corporation announced its first quarter 2025 financial results, highlighted by $39.4 million in RYTELO net product revenue and European Commission approval for RYTELO.

Geron Corporation announces the resignation of John A. Scarlett as CEO and the appointment of Dawn C. Bir as Interim CEO, effective March 10, 2025.

Geron Corporation announced the resignation of John A. Scarlett as President, CEO, and Chairman, and the appointment of Dawn C. Bir as Interim President and CEO, effective March 10, 2025.

Geron Corporation announces positive Q4 2024 financial results, driven by RYTELO sales, and expects to achieve profitability without needing further financing.

Geron Corporation expects to report strong fourth-quarter revenue for RYTELO, with estimated net sales between $45 million and $46 million, and provides an update on operating expenses and cash reserves.

Geron Corporation has secured up to $375 million in funding through a royalty agreement and a debt facility, while also reporting $28.2 million in net product revenue for RYTELO in its first full quarter of sales.

Geron Corporation reported its second quarter 2024 financial results, highlighted by the commercial launch of RYTELO and progress in clinical trials.

The FDA has approved Geron's RYTELO (imetelstat) for treating adult patients with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia.

Geron Corporation successfully held its 2024 Annual Meeting of Stockholders, electing three Class I directors, approving executive compensation, and ratifying Ernst & Young LLP as its auditor.

Geron Corporation announced its first quarter 2024 financial results, highlighted by increased revenue and a net loss, while also updating on the progress of its key clinical trials and commercial preparations.

Geron Corporation has entered into an underwriting agreement for a public offering expected to generate approximately $150 million through the sale of common stock and pre-funded warrants.

Geron Corporation provides an update on risk factors and its corporate presentation, highlighting the ongoing regulatory review for imetelstat and its potential commercial launch.

The FDA's Oncologic Drugs Advisory Committee voted 12 to 2 in favor of Geron's imetelstat for treating transfusion-dependent anemia in lower-risk MDS patients.

Geron Corporation announced its 2023 business highlights and financial results, highlighting progress towards the potential commercial launch of imetelstat and a strong financial position.

The FDA has scheduled an advisory committee meeting to review Geron's New Drug Application for imetelstat, a treatment for transfusion-dependent anemia.